Skip to content

    FRACTAL

    FRACTALGood
    Information Technology·6 Mar 2026
    Management Summary

    Fractal delivered a strong Q3 FY26, characterized by robust 21% revenue growth and a significant profitability milestone as PAT crossed ₹100 crore. Growth was primarily driven by the Healthcare vertical and expansion within existing 'Must Win Clients,' evidenced by a high NRR of 114%. While the company faced headwinds in the CPG and TMT sectors due to macro uncertainties and client-specific issues, management remains committed to its 30% historical growth aspiration and continued R&D investment of 6-8% of revenue.

    Highlights

    8
    • Revenue from operations reached ₹854.4 crores, representing 21% YoY growth (14% in constant currency)

    • Profit After Tax (PAT) crossed the ₹100 crore milestone for the first quarter, up 10% YoY

    • Gross Margin expanded to 47.2%, a 17 bps YoY improvement driven by output-based contracts

    • Life Sciences and Healthcare vertical delivered exceptional 78% YoY growth

    • Net Revenue Retention (NRR) remained strong at 114% for Q3 and 115% for the nine-month period

    • Must Win Clients (MWCs) increased to 127, up from 113 in March 2025

    • Adjusted EBITDA margin stood at 17.8%, up 43 bps YoY despite heavy R&D investments

    • Secured preferred supplier status with two of the 'Magnificent Seven' global technology clients

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹854.4 Cr+21%YoY
    2. 02Gross Margin47.2%
    3. 03Adjusted EBITDA Margin17.8%
    4. 04Profit After Tax₹100 Cr+10%YoY
    5. 05Net Revenue Retention114%

    Segment breakdown

    Life Science and Healthcare
    78% Revenue Growth
    Banking and Financial Services
    26% Revenue Growth
    CPG and Retail
    14.0% Revenue Growth36% Revenue Share
    Telecom, Media, and Technology
    -2% Revenue Growth
    Fractal Alpha
    51% Revenue Growth (9M)₹10 Cr Segment Loss (9M)
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Revenue Growth Aspiration
    30%
    Medium
    Revenue
    Revenue Visibility
    66.6%
    Medium
    Margin
    EBITDA and PAT Margin Expansion
    Expanding
    High
    Other
    R&D Investment as % of Revenue
    6% to 8%
    High

    Risks & concerns

    5
    RiskSeverity

    Macroeconomic and Tariff Uncertainties

    CPG and Retail segment (36% of revenue) impacted by tariff-related headwinds and spending delays.Management acknowledged

    medium

    Associate Company Losses (Qure.ai)

    Share of losses from Qure.ai increased to ₹19 crore from ₹3 crore YoY due to USAID funding cuts.Both acknowledged

    medium

    Client Concentration/Volatility

    Two specific client issues led to degrowth in TMT and APAC, though management notes overall churn remains low at 1%.Management downplayed

    low

    Forex Volatility

    Higher forex losses significantly reduced 'Other Income' from ₹24 crore to ₹2 crore YoY.Management acknowledged

    low

    Areas of Evasion(1)

    • Specific TCV or order book numbers were not disclosed, as management stated the business is 'not run like that'.

    Q&A highlights

    3

    “This year specifically started off with a little bit of the trade headwinds coming from the CPG vertical... If you just exclude that, I think the numbers would be around 26% or so.”

    Explains the temporary gap between current 21% growth and the 30% historical benchmark due to macro factors.

    asked by Kawaljeet Saluja (Kotak Securities)

    2 min read5 chapters

    Detailed Narrative

    01

    Healthcare Vertical Emerges as Primary Growth Engine

    The Life Science and Healthcare segment delivered a standout performance with 78% YoY revenue growth in Q3 FY26. This surge was attributed to strategic investments in building specialized capabilities and the launch of Vaidya 2.0, a verticalized foundation model for healthcare. Management noted that Vaidya 2.0 is the first model to achieve a 50+ score on the OpenAI HealthBench (Hard), positioning Fractal as a leader in medical multimodal reasoning.

    02

    Profitability Milestone and Margin Trajectory

    Fractal crossed the ₹100 crore quarterly PAT milestone, a 10% YoY increase despite a significant jump in losses from associate company Qure.ai (₹19 crore vs ₹3 crore). Gross margins expanded to 47.2%, driven by a shift toward output-based contracts and productivity improvements. Management expects further EBITDA expansion as SG&A and ESOP charges (which fell from 4.9% to 2.8% of revenue) continue to decline as a percentage of sales.

    03

    Resilience in 'Must Win Clients' Strategy

    The company's focus on 'Must Win Clients' (MWCs)—enterprises with >$10B revenue or >$20B market cap—continues to pay off, with the count reaching 127. These clients now contribute 83% of total revenue, up from 81% in FY25. The high Net Revenue Retention of 114% underscores Fractal's ability to expand existing relationships, even as it added 8 percentage points of growth from new client additions during the quarter.

    04

    R&D as a Competitive Moat

    Fractal maintains a high R&D intensity, investing 6-8% of revenue into AI research and product development. Key outputs include PiEvolve, an agentic engine for autonomous machine learning, and Cogentiq, the company's agentic AI platform. Management argues this investment creates a defensible moat against generic IT services firms that lack proprietary AI models and deep domain-specific 'dark data' access.

    05

    Navigating Macro Headwinds in CPG and TMT

    The CPG and Retail vertical, Fractal's largest at 36% of revenue, saw a modest 14% growth due to tariff-related uncertainties and macroeconomic volatility. Similarly, the TMT segment experienced a 2% degrowth, and APAC declined 6%, both linked to specific restructuring at a large telecom client. Management views these as isolated incidents rather than structural shifts, maintaining that overall client churn remains healthy at approximately 1%.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.